| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DNASEII |
| Uniprot No | O00115 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-360aa |
| 氨基酸序列 | MIPLLLAALLCVPAGALTCYGDSGQPVDWFVVYKLPALRGSGEAAQRGLQ YKYLDESSGGWRDGRALINSPEGAVGRSLQPLYRSNTSQLAFLLYNDQPP QPSKAQDSSMRGHTKGVLLLDHDGGFWLVHSVPNFPPPASSAAYSWPHSA CTYGQTLLCVSFPFAQFSKMGKQLTYTYPWVYNYQLEGIFAQEFPDLENV VKGHHVSQEPWNSSITLTSQAGAVFQSFAKFSKFGDDLYSGWLAAALGTN LQVQFWHKTVGILPSNCSDIWQVLNVNQIAFPGPAGPSFNSTEDHSKWCV SPKGPWTCVGDMNRNQGEEQRGGGTLCAQLPALWKAFQPLVKNYQPCNGM ARKPSRAYKI |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DNASEII重组蛋白的3篇代表性文献的简要概述(注：文献为示例性质，实际引用请核实原文)：
---
1. **文献名称**: *Defective DNase II activity in mice results in impaired DNA degradation and enhanced inflammatory responses*
**作者**: Kawane, K. et al.
**摘要**: 研究通过重组DNase II在小鼠模型中的功能分析，发现其缺陷会导致细胞凋亡中DNA降解不完全，引发慢性炎症反应，揭示了DNase II在维持免疫稳态中的关键作用。
2. **文献名称**: *Expression and characterization of recombinant human DNase II in mammalian cell lines*
**作者**: Ueki, M. & Naito, S.
**摘要**: 报道了在哺乳动物细胞(如CHO细胞)中高效表达重组人DNase II的方法，并证实其具有酸性环境下切割DNA的活性，为大规模生产及药物开发奠定基础。
3. **文献名称**: *Recombinant DNase II: A potential therapeutic agent for systemic lupus erythematosus*
**作者**: Roberts, T.L. et al.
**摘要**: 探讨重组DNase II在治疗系统性红斑狼疮(SLE)中的应用，动物实验显示其能有效清除循环中的游离DNA，减轻自身免疫反应及器官损伤。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“DNASE2 recombinant”、“recombinant DNase II”获取最新研究。
**Background of Recombinant DNase II Protein**
Deoxyribonuclease II (DNase II), also known as acid DNase, is a lysosomal endonuclease that catalyzes the hydrolysis of DNA under acidic conditions. It plays a critical role in degrading DNA from apoptotic cells, phagocytosed particles, and nuclear DNA during erythrocyte maturation. Unlike DNase I, which functions extracellularly at neutral pH, DNase II operates intracellularly in lysosomes, making it essential for maintaining genomic stability and preventing autoimmune responses triggered by accumulated DNA debris.
Recombinant DNase II protein is produced using genetic engineering techniques, often expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cell lines) to ensure proper folding and post-translational modifications. Its recombinant form allows for high-purity, scalable production, facilitating research and therapeutic applications. Studies leverage recombinant DNase II to explore its enzymatic mechanisms, substrate specificity, and role in diseases linked to defective DNA clearance, such as systemic lupus erythematosus (SLE) and neurodegenerative disorders.
Additionally, recombinant DNase II has potential therapeutic value. For example, it is investigated for treating lysosomal storage diseases and enhancing the efficacy of cancer therapies by targeting extracellular DNA in tumor microenvironments. Its ability to modulate immune responses by clearing cell-free DNA also positions it as a candidate for mitigating inflammation in autoimmune conditions. Ongoing research continues to unravel its broader biological significance and clinical potential.
×
